T

TC BioPharm Ltd
NASDAQ:TCBP

Watchlist Manager
TC BioPharm Ltd
NASDAQ:TCBP
Watchlist
Price: 0.5 USD -67.53% Market Closed
Market Cap: $63k

Net Margin

-19.8%
Current
Improving
by 5.8%
vs 3-y average of -25.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-19.8%
=
Net Income
£-1m
/
Revenue
£3.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-19.8%
=
Net Income
$-1m
/
Revenue
£3.8m

Peer Comparison

Country Company Market Cap Net
Margin
UK
TC BioPharm Ltd
NASDAQ:TCBP
63k USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in United Kingdom
Percentile
5th
Based on 3 670 companies
5th percentile
-19.8%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

TC BioPharm Ltd
Glance View

Market Cap
63k USD
Industry
Biotechnology

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The firm is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The firm's platform technology allows Company's to design specific therapies to treat a range of cancers and infectious diseases with off the shelf allogeneic gamma delta T cell (GDT) products. The Company’s pipeline includes OmnImmune, ImmuniStim and CAR-T programs. OmnImmune is an unmodified allogeneic gamma delta T cell product, being used for the treatment of acute myeloid leukemia (AML). ImmuniStim is an unmodified allogeneic gamma delta T cell product, being used for the treatment of COVID-19. The firm also provides in-house and partner programs at the pre-clinical stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.

TCBP Intrinsic Value
Not Available
T
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-19.8%
=
Net Income
£-1m
/
Revenue
£3.8m
What is TC BioPharm Ltd's current Net Margin?

The current Net Margin for TC BioPharm Ltd is -19.8%, which is above its 3-year median of -25.6%.

How has Net Margin changed over time?

Over the last 2 years, TC BioPharm Ltd’s Net Margin has increased from -506.8% to -19.8%. During this period, it reached a low of -506.8% on Dec 1, 2021 and a high of -21.2% on Jul 30, 2023.

Back to Top